ESMO Asia 2019 Congress
Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Combination therapy with the programmed cell death ligand 1 inhibitor atezolizumab and the vascular endothelial growth factor inhibitor bevacizumab significantly improved overall and progression-free ...
Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast...
ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast...
ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Combination therapy with the programmed cell death ligand 1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improved overall and progression-free survival in patients with unre...
